- Home
- SWKS vs EXEL Comparison
SWKS vs EXEL Comparison
Compare SWKS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWKS
- EXEL
- Stock Information
- Founded
- SWKS 1962
- EXEL 1994
- Country
- SWKS United States
- EXEL United States
- Employees
- SWKS N/A
- EXEL N/A
- Industry
- SWKS Semiconductors
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SWKS Technology
- EXEL Health Care
- Exchange
- SWKS Nasdaq
- EXEL Nasdaq
- Market Cap
- SWKS 11.4B
- EXEL 10.4B
- IPO Year
- SWKS 1968
- EXEL 2000
- Fundamental
- Price
- SWKS $79.16
- EXEL $38.94
- Analyst Decision
- SWKS Hold
- EXEL Buy
- Analyst Count
- SWKS 19
- EXEL 22
- Target Price
- SWKS $82.88
- EXEL $44.10
- AVG Volume (30 Days)
- SWKS 2.9M
- EXEL 2.9M
- Earning Date
- SWKS 11-04-2025
- EXEL 11-04-2025
- Dividend Yield
- SWKS 3.54%
- EXEL N/A
- EPS Growth
- SWKS N/A
- EXEL 81.76
- EPS
- SWKS 2.50
- EXEL 2.08
- Revenue
- SWKS $4,011,700,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- SWKS N/A
- EXEL $9.14
- Revenue Next Year
- SWKS N/A
- EXEL $12.59
- P/E Ratio
- SWKS $31.62
- EXEL $18.75
- Revenue Growth
- SWKS N/A
- EXEL 10.73
- 52 Week Low
- SWKS $47.93
- EXEL $31.18
- 52 Week High
- SWKS $95.46
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- SWKS 57.53
- EXEL 50.54
- Support Level
- SWKS $73.06
- EXEL $33.76
- Resistance Level
- SWKS $90.90
- EXEL $40.63
- Average True Range (ATR)
- SWKS 3.26
- EXEL 1.30
- MACD
- SWKS 0.55
- EXEL 0.17
- Stochastic Oscillator
- SWKS 42.38
- EXEL 75.47
About SWKS Skyworks Solutions Inc.
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.